Cargando…

Regulation of efferocytosis as a novel cancer therapy

Efferocytosis is a physiologic phagocytic clearance of apoptotic cells, which modulates inflammatory responses and the immune environment and subsequently facilitates immune escape of cancer cells, thus promoting tumor development and progression. Efferocytosis is an equilibrium formed by perfect co...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yunxiang, Yao, Yihan, Deng, Yongchuan, Shao, Anwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199874/
https://www.ncbi.nlm.nih.gov/pubmed/32370748
http://dx.doi.org/10.1186/s12964-020-00542-9
_version_ 1783529229760069632
author Zhou, Yunxiang
Yao, Yihan
Deng, Yongchuan
Shao, Anwen
author_facet Zhou, Yunxiang
Yao, Yihan
Deng, Yongchuan
Shao, Anwen
author_sort Zhou, Yunxiang
collection PubMed
description Efferocytosis is a physiologic phagocytic clearance of apoptotic cells, which modulates inflammatory responses and the immune environment and subsequently facilitates immune escape of cancer cells, thus promoting tumor development and progression. Efferocytosis is an equilibrium formed by perfect coordination among “find-me”, “eat-me” and “don’t-eat-me” signals. These signaling pathways not only affect the proliferation, invasion, metastasis, and angiogenesis of tumor cells but also regulate adaptive responses and drug resistance to antitumor therapies. Therefore, efferocytosis-related molecules and pathways are potential targets for antitumor therapy. Besides, supplementing conventional chemotherapy, radiotherapy and other immunotherapies with efferocytosis-targeted therapy could enhance the therapeutic efficacy, reduce off-target toxicity, and promote patient outcome.
format Online
Article
Text
id pubmed-7199874
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71998742020-05-06 Regulation of efferocytosis as a novel cancer therapy Zhou, Yunxiang Yao, Yihan Deng, Yongchuan Shao, Anwen Cell Commun Signal Review Efferocytosis is a physiologic phagocytic clearance of apoptotic cells, which modulates inflammatory responses and the immune environment and subsequently facilitates immune escape of cancer cells, thus promoting tumor development and progression. Efferocytosis is an equilibrium formed by perfect coordination among “find-me”, “eat-me” and “don’t-eat-me” signals. These signaling pathways not only affect the proliferation, invasion, metastasis, and angiogenesis of tumor cells but also regulate adaptive responses and drug resistance to antitumor therapies. Therefore, efferocytosis-related molecules and pathways are potential targets for antitumor therapy. Besides, supplementing conventional chemotherapy, radiotherapy and other immunotherapies with efferocytosis-targeted therapy could enhance the therapeutic efficacy, reduce off-target toxicity, and promote patient outcome. BioMed Central 2020-05-05 /pmc/articles/PMC7199874/ /pubmed/32370748 http://dx.doi.org/10.1186/s12964-020-00542-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zhou, Yunxiang
Yao, Yihan
Deng, Yongchuan
Shao, Anwen
Regulation of efferocytosis as a novel cancer therapy
title Regulation of efferocytosis as a novel cancer therapy
title_full Regulation of efferocytosis as a novel cancer therapy
title_fullStr Regulation of efferocytosis as a novel cancer therapy
title_full_unstemmed Regulation of efferocytosis as a novel cancer therapy
title_short Regulation of efferocytosis as a novel cancer therapy
title_sort regulation of efferocytosis as a novel cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199874/
https://www.ncbi.nlm.nih.gov/pubmed/32370748
http://dx.doi.org/10.1186/s12964-020-00542-9
work_keys_str_mv AT zhouyunxiang regulationofefferocytosisasanovelcancertherapy
AT yaoyihan regulationofefferocytosisasanovelcancertherapy
AT dengyongchuan regulationofefferocytosisasanovelcancertherapy
AT shaoanwen regulationofefferocytosisasanovelcancertherapy